- Home
- DMRC vs UNCY Comparison
DMRC vs UNCY Comparison
Compare DMRC & UNCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | DMRC | UNCY |
|---|---|---|
| Founded | 2008 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 183.5M | 150.1M |
| IPO Year | 2026 | 2021 |
Fundamental Metrics
Financial Performance| Metric | DMRC | UNCY |
|---|---|---|
| Price | $7.24 | $5.32 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 3 |
| Target Price | $10.00 | ★ $25.67 |
| AVG Volume (30 Days) | 108.2K | ★ 795.7K |
| Earning Date | 05-12-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $675,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $582.86 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $4.07 | $3.72 |
| 52 Week High | $17.47 | $8.74 |
Technical Indicators
Market Signals| Indicator | DMRC | UNCY |
|---|---|---|
| Relative Strength Index (RSI) | 48.82 | 48.45 |
| Support Level | $6.33 | $5.28 |
| Resistance Level | $8.24 | $5.96 |
| Average True Range (ATR) | 0.61 | 0.30 |
| MACD | 0.19 | 0.08 |
| Stochastic Oscillator | 59.13 | 74.82 |
Price Performance
Historical ComparisonAbout DMRC Digimarc Corporation
Digimarc Corp is a product digitization company delivering business value across industries through identities and cloud-based solutions. Its solutions are Anti-counterfeiting, Internal Compliance, Leak Detection, Piracy Prevention, Product Swap Prevention, Provenance & Authenticity (C2PA), Recycling, and Royalty Monitoring. The group offers services to various industries such as Consumer Packaged Goods, Government, Media, Pharmaceutical, and Retail.
About UNCY Unicycive Therapeutics Inc.
Unicycive Therapeutics Inc is a clinical-stage biotechnology company focused on identifying, developing, and commercializing therapies to address unmet medical needs, with a primary focus on kidney disease. The company is advancing two key product candidates: oxylanthanum carbonate (OLC), a phosphate binder for the treatment of hyperphosphatemia in chronic kidney disease patients on dialysis, and UNI-494, a drug candidate for the treatment of acute kidney injury.